ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently Zhou H, et al. have reported that the inhibition of β-catenin and BCR-ABL decreases CD44 levels in K562 cells, in stem/progenitor cells in blastic crisis of CML samples as well as on in vivo models.